Neutralizing AAV antibody titers
| . | Baseline . | ∼1 mo . | ∼6 mo . |
|---|---|---|---|
| A | 1:1007-150 | 1:50007-150 | 1:1000 |
| B | 1:10007-150 | 1:10 0007-150 | 1:10 000 |
| C | 1:107-150 | 1:10 0007-150 | 1:1000 |
| D | 1:100 | 1:10 000 | 1:10 000 |
| E | 1:100 | 1:1000 | 1:1000 |
| F | 1 | 1:1000 | 1:1000 |
| G | 1:100 | 1:10 000 | 1:10 000 |
| H | NS | NS | 1:1000 |
| . | Baseline . | ∼1 mo . | ∼6 mo . |
|---|---|---|---|
| A | 1:1007-150 | 1:50007-150 | 1:1000 |
| B | 1:10007-150 | 1:10 0007-150 | 1:10 000 |
| C | 1:107-150 | 1:10 0007-150 | 1:1000 |
| D | 1:100 | 1:10 000 | 1:10 000 |
| E | 1:100 | 1:1000 | 1:1000 |
| F | 1 | 1:1000 | 1:1000 |
| G | 1:100 | 1:10 000 | 1:10 000 |
| H | NS | NS | 1:1000 |
293 cells were incubated with serial dilutions of patient serum and transduced with AAV lacZ. Sera scored positive for neutralizing AAV antibodies if β-galactosidase activity is 50% or less of that observed when rAAV-lacZ was preincubated with negative control mouse sera.
NS indicates no sample.
See Kay et al.24